Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma share news and announcements
683 announcements, routine notices left out, newest first. Page 10 of 14.
Nov 2017
Oct 2017
Sep 2017
27 Sep · Meeting
Aug 2017
11 Aug · Business
11 Aug · Results
Jul 2017
May 2017
29 May · Business
29 May · Results
10 May · Business
Apr 2017
Feb 2017
6 Feb · Results
Jan 2017
Nov 2016
12 Nov · Results
Oct 2016
Sep 2016
30 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
Aug 2016
25 Aug · Limited Review Report
May 2016
30 May · Business
Apr 2016
Mar 2016
Feb 2016
Jan 2016
25 Jan · News Verification
Exchange had sought clarification from Marksans Pharma Limited on January 13, 2016 with respect to news item captioned "Marksans Pharma's Goa Plant gets notification of deficiency in GMP from UK MHRA, 40% of Marksans Pharma's revenue comes from UK". The company has submitted its response on the same on Jan 13,2016.Exchange has received further submission from the company on the above news item . The Company has inter-alia stated that, "Marksans Goa plant is approved by US FDA and UK MHRA and this information is in the public domain. US FDA, UK MHRA and other Health Authorities regularly inspect the plant. Since periodical inspection of the plant is a normal process, the Company do not inform the exchanges regarding such audit. Issue of observation and response thereto is also in the normal course of audit process. In the present event, audit has taken place and UK MHRA has issued observation. The company has responded to the observation and further feedback is awaited from them. The audit is still open and UK MHRA is evaluating the Company's response to the observation".